Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vor Biopharma Inc.VOR · Entity 4763 | Director | June 11, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vor Biopharma Inc.
Report date June 11, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-10 | Direct | 57,162 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 57,162 · Balance 57,162 F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 13, 2026 00:41 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (right to buy) · Derivative | 57,162 | $0.00 Strike: $14.09 | $0.00 |
DisclosureSEC source: 0001193125-26-269998 · ownership.xml · derivative · entry 1 Kalir Erez · CIK 0001512447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,162 Underlying: Common stock · 57,162 shares Expires 2036-06-10 F1 · derivative.exercise_date: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 21:45 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001415889-25-014532 · form4-05232025_050513.xml · derivative · entry 1 Kalir Erez · CIK 0001512447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-05-21 F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:41 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-25-001155 · form4-01082025_110101.xml · derivative · entry 1 Kalir Erez · CIK 0001512447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-01-05 F1 · derivative.exercise_date: One thirty-sixth of the shares subject to the option shall vest and become exercisable on February 6, 2025 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.